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Nebert and Menon introduce their paper by writing: 'Pharmacogenetic differences can be 10-to more than 40-fold between individuals within an 'ethnic' group, while the mean variation between ethnic groups is rarely more than 2-to 3-fold.' This is a crucial argument in their review which is repeated three times. They call this observation the hallmark of complex or multifactorial traits, although it is also valid when there are cases of monogenically controlled drug response.
Nebert and Menon's statement appears to discount the importance of mean differences between populations, a rejection which deserves critical remarks. At the same time, their statement raises the question how to properly deal with population means when a drug response is multifactorially determined.
Most genes are identical in the different human races; ethnic differences represent distinctions between a tiny portion of human genes, and therefore are at least in part negligible. In fact, even chimpanzees and humans share most genes, and it is a small proportion of their genes which render them different species. It is in this sense, that the average of a genetically controlled factor does not mean very much. However, from pharmacogenetics we have learned that the presence of a single variant gene may cause a person to be killed by a drug that is safely taken by the majority of people.
Thus, when we deal with drugs, average similarities may indeed mean very little. What counts is frequency and extent with which some selected genes differ between populations.
In other words, important is whether the 'proportion of exceptional subjects' differs between populations. It deserves to be emphasized that these proportions can be strongly influenced by population means: such proportions may differ substantially even if the population means differ only moderately. Mathematically, what counts here are the edges or rims of the distribution curves. This concept has been explained in several earlier publications. The curve in Figure 1 shows the standard distribution of the drug metabolizing capacities around two population means. Toxic effects of the drug may be confined to people with low catalytic capacity; the threshold activity below which toxicity occurs is represented here by the symbol X 0 . If two such curves, representing studies of two populations, have even moderately different averages but equal standard deviations, the proportion of sensitive subjects may differ substantially (Table 1) . For instance, if the mean of population B is one standard deviation below that of population A, and if 10% of A would experience toxicity, almost four times as many people in population B are expected to show toxicity. If 1% of population A shows toxicity, it would be close to 10% in population B. Importantly, the percentage difference between the populations increases with a shift of X 0 toward the edge of the curves. Thus, looking at the population averages may help one to note a medically significant difference in the proportion of subjects who suffer toxicity from a drug. X 0 represents the threshold catalytic activity below which clinical toxicity is experienced. For example, when X 0 = 10%, it is assumed that 10% of the population exhibits a catalytic activity indicative of clinical toxicity.
Comparative toxicity risk between the population A and the population B is calculated by the ratio of the number of individuals who display a slow catalytic activity below X 0 in population B (slower activity) vs population A (faster activity). Note that even a small 0.1 SD difference in mean catalytic activity between the two populations may be reflected by a 29% increase in risk for toxicity in population B when the X 0 is set at 1%. Splus 4.5 (MathSoft, WA, USA) was used to evaluate the normal and inverse normal cumulative distribution functions and the area under the curves.
The main purpose of the paper by Nebert and Menon seems to advise governments not to mandate a routine inclusion of ethnic minorities in all clinical studies. The paper rightly calls for scientific reasoning in all such decisions; any knowledge of established, particular allele frequencies may produce a better choice between populations than selection simply by ethnicity. However, the inclusion of Reply to Kalow 
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In response to our invited 'Perspectives' article in the maiden issue of The Pharmacogenomics Journal, 1 Kalow, Ozdemir and Tothfalusi 2 express concern about our statement, 'Pharmacogenetic differences can be 10-to more than 40-fold between individuals within an ethnic group, while the mean variation between ethnic groups is rarely more than 2-to 3-fold; this observation is the hallmark of complex (or multifactorial) traits.' They go on to say, 'This is a crucial argument www.nature.com/tpj an ethnic minority in a clinical study may reveal information on the frequency of an unknown genetic variant which affects a drug response; such information can be of clinical importance and may increase the safety of some members of that ethnic population. This fact favors the inclusion of ethnic minorities in clinical studies.
It is important to note that differences in population means may in their review, . . .' Actually, this was not intended to be 'a crucial argument,' and what follows is our attempt to clarify our intentions in that invited 'Perspectives' article.
Later, Kalow and coworkers 2 say, 'The main purpose of the paper by Nebert and Menon seems to advise governments not to mandate a routine inclusion of ethnic minorities in all clinical studies.' The subject of our article was primarily concerned with the public's perception of 'race,' how underestimate the clinically important changes at the edges of a population. Furthermore, the more rare a pharmacological trait is, the more it will be influenced by changes in population means.
incredibly admixed almost all human populations are in the present day, and how alleles of the three major races have diverged.
Kalow et al 2 state further, '(this observation) is also valid when there are cases of monogenically controlled drug responses,' and proceed to discuss the 'Edge Effect'-which was originally presented as Figure 3 in the Kalow and Bertilsson 1994 review. 3 We completely agree with their central tenet that the proportion of subjects 'on the edge' can be strongly influenced by the population mean, even if the population means differ only moderately; in fact, one of us (DWN) uses this 'Edge Effect concept' as a slide in several (pharmacology, pharmacy, occupational medicine) teaching sessions with students each year.
The concept of a 'monogenically controlled drug response' or a 'monogenic inborn-error-of-metabolism,'
